-
结直肠癌(colorectal cancer,CRC)是全世界常见的消化道恶性肿瘤之一。相关研究数据表明,近几年我国CRC的发病率和死亡率均保持上升趋势[1]。早期肿瘤病人可通过手术切除获得良好预后,其5年生存率可超过90%。然而多数CRC确诊时已为中晚期,无法达到理想的治疗效果,5年生存率不到10%[2]。CRC中常常有代谢失常的表现[3]。泛醌-细胞色素c还原酶复合物核心蛋白1(ubiquinol cytochrome c reductase core protein 1,UQCRC1)是线粒体复合体Ⅲ的重要结构亚基之一,参与组成线粒体氧化呼吸链,对维持正常线粒体功能和细胞代谢有着基础性作用[4]。国内外大量研究表明,UQCRC1在人类肿瘤中存在表达失调[5]。癌胚抗原(carcinoembryonic antigen,CEA)是目前应用最广泛的肿瘤标志物之一,经常用于肠癌的检测中。但因其特异性与敏感性欠佳,常与其他肿瘤标志物联合使用[6]。本研究通过检测CRC根治术后的组织标本中UQCRC1的表达,分析其和血清CEA的相关性,初步探讨UQCRC1在结肠癌发生、发展过程中的作用及意义。
-
UQCRC1主要表达于细胞质(见图 1)。本次研究结果显示,52例癌组织中有16例(30.8%)UQCRC1低表达;37例癌旁正常组织中UQCRC1呈低表达的有4例(10.8%),在α < 0.05的水准上,两者差异具有统计学意义(χ2=4.94,P < 0.05)。Spearman等级相关性分析结果提示UQCRC1的表达与组织性质显著相关(r=-0.236, P < 0.05)。CRC病人术前血清CEA阳性率为40.4%(21/52)。
-
CRC组织中UQCRC1的表达与淋巴结转移情况有关(P < 0.05),在病人不同性别、年龄、肿瘤大小、分化程度、临床分期上的表达差异均无统计学意义(P>0.05) (见表 1)。
临床病理参数 n UQCRC1 χ2 P 低表达 高表达 性别 男
女28
247(25.0)
9(37.5)21(75.0)
15(62.5)0.95 >0.05 年龄/岁 ≤60
>6027
2510(37.0)
6(24.0)17(63.0)
19(76.0)1.04 >0.05 肿瘤大小/cm ≤5
>527
259(33.3)
7(28.0)18(66.7)
18(72.0)0.17 >0.05 分化程度 低分化
中+高分化16
363(18.8)
13(36.1)13(81.3)
23(63.9)0.86* >0.05 临床分期 Ⅰ+Ⅱ
Ⅲ+Ⅳ24
285(20.8)
11(39.3)19(79.2)
17(60.7)2.07 >0.05 淋巴结转移 是
否22
3010(45.5)
6(20.0)12(54.5)
24(80.0)3.86 < 0.05 *示校正χ2值 表 1 CRC组织中UQCRC1的表达与临床及病理参数的关系[n; 百分率(%)]
-
52例结肠癌组织中,UQCRC1表达阴性同时CEA表达阳性者占62.5%(10/16)。运用Spearman等级相关分析得知,在α < 0.05的检验水准上,CRC病人癌组织中UQCRC1表达水平与术前血清CEA值呈显著负相关(r=-0.300)(P < 0.05)(见表 2)。
UQCRC1表达 n CEA表达 r P 阳性 阴性 阴性
阳性16
3610
116
25-0.300 < 0.05 表 2 CRC中UQCRC1、CEA表达的相关性(n)
UQCRC1在结直肠癌组织中的表达及其与血清CEA的相关性
Expression of UQCRC1 in colorectal cancer tissue and its correlation with serum CEA
-
摘要:
目的探讨结直肠癌组织中泛醌-细胞色素c还原酶复合物核心蛋白1(UQCRC1)的表达及其与血清癌胚抗原(CEA)的相关性。 方法收集52例结直肠癌组织蜡块及37例癌旁组织蜡块,采用免疫组化SP法检测UQCRC1的表达水平,分析其表达与结直肠癌临床病理特征以及血清CEA值的相关性。 结果UQCRC1在癌组织中表达下调率为30.8%,在癌旁正常组织中表达下调率为10.8%,两者差异有统计学意义(χ2=4.94,P < 0.05)。且其表达与结直肠癌淋巴结转移有关,伴有淋巴结转移的病人阴性表达率(45.5%)高于不伴有淋巴有转移的病人(20.0%),两者差异有统计学意义(P < 0.05);癌组织中UQCRC1表达与术前血清CEA水平呈负相关(r=-0.300,P < 0.05)。 结论UQCRC1在结直肠癌中的表达下调在肿瘤发生、发展中发挥重要作用,联合血清CEA可为结直肠癌的病情评估提供理论依据。 -
关键词:
- 结直肠肿瘤 /
- 泛醌-细胞色素c还原酶复合物核心蛋白1 /
- 癌胚抗原 /
- 免疫组织化学
Abstract:ObjectiveTo investigate the expression levels of ubiquinol cytochrome c reductase core protein 1(UQCRC1) in colorectal cancer tissues, and its correlation with serum carcinoembryonic antigen(CEA) level. MethodsThe expression levels of UQCRC1 in 52 cases of colorectal cancer tissue and 37 cases of paracancer tissue were detected using the immunochemistry SP method, and the relationship between the expression levels of UQCRC1, and clinicological characteristics of colorectal cancer and serum level of CEA were analyzed. ResultsThe down-regulation rates of UQCRC1 in cancer tissue and normal tissue adjacent to cancer were 30.8% and 10.8%, respectively, and the difference of which was statistically significant(χ2=4.94, P < 0.05).The UQCRC1 expression was related to lymph node metastasis of colorectal cancer, and the negative expression rate in patients with lymph node metastasis(45.5%) was higher than that in patients without lymph node metastasis(20.0%)(P < 0.05).The UQCRC1 expression in cancer tissue was negatively correlated with the preoperative serum CEA level(r=-0.300, P < 0.05). ConclusionsThe down-regulation of UQCRC1 expression in colorectal cancer may play an important role in tumorigenesis and development, and UQCRC1 combined with serum CEA can provide the theoretical basis in the assessment of colorectal cancer. -
表 1 CRC组织中UQCRC1的表达与临床及病理参数的关系[n; 百分率(%)]
临床病理参数 n UQCRC1 χ2 P 低表达 高表达 性别 男
女28
247(25.0)
9(37.5)21(75.0)
15(62.5)0.95 >0.05 年龄/岁 ≤60
>6027
2510(37.0)
6(24.0)17(63.0)
19(76.0)1.04 >0.05 肿瘤大小/cm ≤5
>527
259(33.3)
7(28.0)18(66.7)
18(72.0)0.17 >0.05 分化程度 低分化
中+高分化16
363(18.8)
13(36.1)13(81.3)
23(63.9)0.86* >0.05 临床分期 Ⅰ+Ⅱ
Ⅲ+Ⅳ24
285(20.8)
11(39.3)19(79.2)
17(60.7)2.07 >0.05 淋巴结转移 是
否22
3010(45.5)
6(20.0)12(54.5)
24(80.0)3.86 < 0.05 *示校正χ2值 表 2 CRC中UQCRC1、CEA表达的相关性(n)
UQCRC1表达 n CEA表达 r P 阳性 阴性 阴性
阳性16
3610
116
25-0.300 < 0.05 -
[1] 黄陈, 戎泽印. 结直肠癌诊治新进展[J]. 蚌埠医学院学报, 2018, 43(10): 1293. [2] 张政, 李鹏, 张澍田. 中国结直肠癌筛查的研究历史现状与展望[J]. 中国实用内科杂志, 2018, 38(9): 777. [3] 杨伟兴, 喻玉, 肖王, 等. 结肠癌中NMNAT2、p53的表达及三者相关性研究[J]. 现代生物医学进展, 2019, 19(14): 2735. [4] TORRICELLI F, SAXENA A, NUAMAH R, et al. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy[J]. Eur J Cancer, 2020, 132: 104. doi: 10.1016/j.ejca.2020.03.002 [5] ZHAO X, WANG Q, LIN F, et al. RNA Sequencing of Osteosarcoma Gene Expression Profile Revealed that miR-214-3p Facilitates Osteosarcoma Cell Proliferation via Targeting Ubiquinol-Cytochrome c Reductase Core Protein 1(UQCRC1)[J]. Med Sci Monit, 2019, 25: 4982. doi: 10.12659/MSM.917375 [6] 谭杨波, 廖桂红, 陈龙, 等. 肿瘤标志物在结直肠癌诊断应用中的研究新进展[J]. 卫生职业教育, 2019, 37(6): 158. [7] 国家卫生计生委医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J]. 中华普通外科学文献, 2018, 38(10): 1089. [8] HU X, LI YQ, LI QG, et al. ITGAE Defines CD8+ Tumor-Infiltrating Lymphocytes Predicting a better Prognostic Survival in Colorectal Cancer[J]. EBioMedicine, 2018, 35: 178. doi: 10.1016/j.ebiom.2018.08.003 [9] TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J]. Med Sci (Basel), 2018, 6(2): 31. [10] 刘晓雪, 宇传华, 周薇, 等. 中国近30年间结直肠癌死亡趋势分析[J]. 中国癌症杂志, 2018, 28(3): 177. [11] SHAN W, LI J, XU W, et al. Critical role of UQCRC1 in embryo survival, brain ischemic tolerance and normal cognition in mice[J]. Cell Mol Life Sci, 2019, 76(7): 1381. doi: 10.1007/s00018-019-03007-6 [12] KULAWIEC M, ARNOUK H, DESOUKI MM, et al. Proteomic Analysis of Mitochondria-to-Nucleus Retrograde Response in Human Cancer[J]. Cancer Biol Ther, 2006, 5(8): 967. doi: 10.4161/cbt.5.8.2880 [13] WANG X, ZHI Q, LIU S, et al. Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach[J]. Sci Rep, 2016, 6(1): 38871. doi: 10.1038/srep38871 [14] WANG Q, LI M, GAN Y, et al. Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer[J]. Theranostics, 2020, 10(5): 2141. doi: 10.7150/thno.38704 [15] SHIBANUMA M, INOUE A, USHIDA K, et al. Importance of mitochondrial dysfunction in oxidative stress response: A comparative study of gene expression profiles[J]. Free Radic Res, 2011, 45(6): 672. doi: 10.3109/10715762.2011.564169 [16] HUANG S, WANG J, CUI Y. 2, 2', 4, 4'-Tetrabromodiphenyl ether injures cell viability and mitochondrial function of mouse spermatocytes by decreasing mitochondrial proteins Atp5b and Uqcrc1[J]. Environ Toxicol Pharmacol, 2016, 46: 301. doi: 10.1016/j.etap.2016.08.011 [17] YI T, WU X, LONG Z, et al. Overexpression of Ubiquinol-Cytochrome c Reductase Core Protein 1 May Protect H9c2 Cardiac Cells by Binding with Zinc[J]. Biomed Res Int, 2017, 2017: 1314297. [18] ZHU Y, DEAN AE, HORIKOSHI N, et al. Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy[J]. J Clin Invest, 2018, 128(9): 3682. doi: 10.1172/JCI120844 [19] GUERRA F, ARBINI AA, MORO L. Mitochondria and cancer chemoresistance[J]. Biochim Biophys Acta Bioenerg, 2017, 1858(8): 686. doi: 10.1016/j.bbabio.2017.01.012 [20] ZONG WX, RABINOWITZ JD, WHITE E. Mitochondria and Cancer[J]. Mol Cell, 2016, 61(5): 667. doi: 10.1016/j.molcel.2016.02.011 [21] IDELCHIK MDPS, BEGLEY U, BEGLEY TJ, et al. Mitochondrial ROS control of cancer[J]. Semin Cancer Biol, 2017, 47: 57. doi: 10.1016/j.semcancer.2017.04.005 [22] YANG S, LIAN G. ROS and diseases: role in metabolism and energy supply[J]. Mol Cell Biochem, 2020, 467(1/2): 1. doi: 10.1007/s11010-020-03697-8 [23] ZHUANG J, PAN ZJ, LI MQ, et al. BDE-47 induced apoptosis in zebrafish embryos through mitochondrial ROS-mediated JNK signaling[J]. Chemosphere, 2020, 258: 127385. doi: 10.1016/j.chemosphere.2020.127385 [24] MOLONEY JN, COTTER TG. ROS signalling in the biology of cancer[J]. Semin Cell Dev Biol, 2018, 80: 50. doi: 10.1016/j.semcdb.2017.05.023 [25] LI W, WUBULIKASIMU G, ZHAO X, et al. UQCRC1 downregulation is correlated with lymph node metastasis and poor prognosis in CRC[J]. Eur J Surg Oncol, 2019, 45(6): 1005. doi: 10.1016/j.ejso.2019.02.025 [26] ZONG S, LI H, SHI Q, et al. Prognostic significance of VEGF-C immunohistochemical expression in colorectal cancer: A meta-analysis[J]. Clin Chim Acta, 2016, 458: 106. doi: 10.1016/j.cca.2016.04.037 [27] LEE JH, LEE SW. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches[J]. Gastroenterol Res Pract, 2017, 2017: 7521987. [28] 孙磊, 张守永, 广圣芳, 等. CA153、CEA与细针吸取细胞学联合检测在乳腺癌诊断中的价值[J]. 蚌埠医学院学报, 2018, 43(3): 391. [29] 曾艳, 张力, 贺帅. 结直肠癌患者血清CEA和CA19-9水平与肝转移的关系[J]. 癌症进展, 2019, 17(13): 1586. [30] 赵建峰, 李记彬, 石刚, 等. 结直肠癌AIM2和血清CEA表达水平及其临床意义[J]. 中华结直肠疾病电子杂志, 2019, 8(3): 257. doi: 10.3877/cma.j.issn.2095-3224.2019.03.009